Manage your formulary budget
Anticipate generic drug launch
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Method of lowering serum prolactin|
|Abstract:||Benzodiazepine derivatives which have tranquillizing activity, especially 1,4-benzodiazepine derivatives, can lower the serum prolactin concentration. They can reduce, dosage-dependently, the increase in the serum prolactin concentration induced by the administration of neuroleptics, which can lead to undesirable side-effects, when about 0.01 to 100 parts by weight of benzodiazepine derivatives are administered per part by weight of neuroleptic, it being immaterial whether the benzodiazepine derivative is administered before or after the neuroleptic or simultaneously therewith. The simultaneous administration of the active substances can be carried out as an ad hoc combination or in the form of a pharmaceutical combination.|
|Inventor(s):||Lotz; Wolfgang (Bad Krozingen, DE)|
|Assignee:||Hoffmann-La Roche Inc. (Nutley, NJ)|
1. A method of treatment for individuals having a high prolactin concentration induced by the administration of a neuroleptic selected from the group consisting of
chlorpromazine, methopromazine, reserpine, tetrabenazine, benzindopyrine, sulpiride, metoclopramide, haloperidol and thioridazine which comprises the administration of a prolactin lowering amount of a benzodiazepine derivative selected from the group
consisting of chlordiazepoxide, diazepam, flunitrazepam, clonazepam, flurazepam, medazepam, bromazepam, lorazepam, oxazepam, prazepam, temazepam, cloxazolam, oxazolam and triazolam to such individual.
2. The method of claim 1 wherein the 1,4-benzodiazepine derivative is nitrazepam.
3. The method of claim 1 wherein the neuroleptic is sulpiride or haloperidol.
4. The method of claim 1 wherein about 0.01 to 100 parts by weight of benzodiazepine derivative are used per part by weight of neuroleptic.
5. The method of claim 4 wherein 0.05 to 40 parts by weight of benzodiazepine derivative are used per part by weight of neuroleptic.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.